Also, Bellanti et al. [40] investigated the effects of SGLT2 inhibitors on markers of oxidative stress, inflammation, liver steatosis, and fibrosis in 52 patients of T2D with NAFLD. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.